Lightbridge Corporation — Q3 2015 Form 10-Q
Reporting period: Three and nine months ended September 30, 2015. Financial statements are unaudited; 2014 comparative figures were restated.
Business context
Lightbridge develops advanced metallic nuclear fuel and provides nuclear-sector consulting. All reported revenue came from consulting; the technology business had no revenue. Consulting work was concentrated in the UAE and other international markets.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 restated | Nine months 2015 | Nine months 2014 restated |
|---|---|---|---|---|
| Revenue | $234,163 | $275,158 | $656,220 | $878,396 |
| Gross profit / margin | $115,209 / 49% | $139,097 / 51% | $204,213 / 31% | $386,349 / 44% |
| Operating loss | $1,254,869 | $760,619 | $3,812,510 | $3,850,640 |
| Net income (loss) | $(174,271) | $95,996 | $(1,076,613) | $(5,063,393) |
| Basic and diluted EPS | $(0.01) | $0.01 | $(0.06) | $(0.34) |
- Q3 revenue declined 15% year over year; nine-month revenue fell 25%. Management attributed the decrease to less work on ENEC, FANR and other consulting projects.
- Nine-month operating expenses were $4.02 million, including $3.11 million general and administrative and $0.91 million research and development. G&A was broadly flat year over year; R&D declined 22% for the nine-month period but rose in Q3.
- Nine-month operating cash use was $2.54 million, versus $3.43 million in 2014; investing cash use was $60,000 and financing cash provided was $55,000. Cash and equivalents ended at $1.68 million; restricted cash was $326,000.
- At September 30, total assets were $3.26 million, current liabilities $608,000, total liabilities $2.50 million, and stockholders’ equity $762,000. The $1.89 million warrant liability is a fair-value accounting liability. The company reported no debt or bank credit lines.
Material changes, outlook and risks
- Restatement: The Audit Committee determined that prior warrant accounting was incorrect. Warrants with a cash-settlement feature were reclassified from equity to derivative liabilities, with fair-value changes recorded in earnings. Restated 2014 results reflect this noncash adjustment; the company said cash position and cash flows were unaffected. The restatement reduced December 2014 stockholders’ equity by $4.63 million.
- Liquidity: Management reported a current operating cash shortfall averaging about $300,000 monthly and said September working capital of approximately $1.8 million was insufficient for the next 12 months absent financing or other changes. It expected the ATM and Aspire Capital facilities to provide sufficient working capital, while acknowledging financing uncertainty.
- Funding arrangements: Aspire Capital committed to purchase up to $10 million of shares over two years, subject to the company’s election and conditions. The ATM had a remaining limit of approximately $207,000 as of the filing date. These are potential funding sources, not guaranteed proceeds.
- R&D plans: Management expected to spend about $3 million on fuel development over the next 12–15 months. Plans included sample fabrication at Canadian Nuclear Laboratories and irradiation testing at Norway’s Halden reactor, expected to begin in 2017. Commercial deployment and licensing remain subject to technical and regulatory milestones.
- Controls and reporting: Management concluded disclosure controls were ineffective because of a material weakness in warrant accounting. It described remediation plans but gave no assurance they would succeed.
- Concentration and other risks: Revenue depended heavily on a small number of international customers; ENEC and FANR accounted for 78% of Q3 revenue. Risks include contract renewal/work-plan variability, access to capital, nuclear-market conditions, technology commercialization, regulation and international operations.
- Contingency: A former CFO’s Virginia lawsuit was voluntarily dismissed without prejudice in November 2015 and could be refiled; a related OSHA complaint remained. The company said it viewed the claims as without merit.
- Unusual noncash item: Warrant revaluation generated $2.74 million of income for the nine months, materially reducing the reported net loss; it did not provide operating cash.
Investor facts to verify
- Whether the warrant-accounting control weakness has been remediated and whether further restatements are possible.
- Actual cash burn, financing proceeds and dilution from the Aspire Capital and ATM arrangements.
- Renewals, work plans and revenue contribution from ENEC, FANR and other major consulting customers.
- Progress, costs and regulatory approvals for the fuel fabrication and Halden irradiation milestones.
- Status and potential exposure of the former CFO’s claims and any subsequent developments.